Cancer Medications and Support Programs | Eli Lilly and Company
Lilly is dedicated to developing innovative new cancer medicines. Learn about those now available and in the oncology pipeline.
Lilly Oncology Pipeline Database - View Statuses & Resources
Explore our oncology pipeline database, discover promising therapies in development for diverse unmet medical needs, and download HCP resources
Oncology, Healthcare Professional - Eli Lilly and Company
To search for medical information, please select a product or browse by the listed therapeutic areas below. If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cancer Clinical Trials | Lilly Oncology Research - Lilly Trials
Lilly partners with clinical trial volunteers to develop new cancer and oncology treatment options. Learn more about cancer research and find Lilly trials here.
Lilly Scientific Oncology Presentations | Eli Lilly and Company
Dec 10, 2024 · Access Scientific Information Page for Lilly Oncology Presentations Presented at SABCS 2024
Financial Assistance Options | Lilly Oncology Support Center
Through Lilly Support Services, we aim to offer support for eligible patients prescribed Lilly's cancer treatments. For those who qualify, we can help with: Understanding insurance coverage. Reviewing financial assistance options, including those available through savings card programs and independent patient-assistance foundations.
Cancer | Disease Areas - Eli Lilly and Company
Whether it's treating rare tumour types, leveraging precision medicine, continuing the study of immuno-oncology or discovering new ways to advance existing treatments, we're dedicated to making even greater differences in the lives of people living with cancer.
Lilly Announces Agreement To Acquire Loxo Oncology
Jan 7, 2019 · Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion.
Lilly to Acquire POINT Biopharma to Expand Oncology …
Oct 3, 2023 · Lilly will commence a tender offer to acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion) payable at closing. The transaction has been approved by the boards of directors of both companies.
Cancer | Disease Areas | Lilly UK
Whether it's treating rare tumor types, leveraging precision medicine, continuing the study of immuno-oncology or discovering new ways to advance existing treatments, we're dedicated to making even greater differences in the lives of people living with cancer.